Start

Indications for Starting and Continuing Hydroxyurea Therapy in a Patient with Sickle Cell Disease

Specialty:

Allergy, Immunology, Anesthesiology, Cardiology, Dermatology, Endocrinology, Diabetes, Metabolism, Emergency Medicine, Family, General Practice, Geriatrics, Internal Medicine, Medical Genetics, Neurological Surgery, Neurology, Obstetrics, Gynecology, Oncology, Ophthalmology, Orthopedics, Otolaryngology, Pathology, Pediatrics, Physical Medicine and Rehabilitation, Plastic Surgery, Preventive Medicine, Psychiatry, Radiology, Surgery, Urology, Other

Objective:

ICD-10:

Description:

Hydroxyurea may have a number of beneficial effects in patients with sickle cell disease. It can result in an increase in hemoglobin F concentration and reduce neutrophils, monocytes and reticulocytes. Its use may be limited by the development of unacceptable myelotoxicity or by a failure to show improvement.

To read more or access our algorithms and calculators, please log in or register.

RECENT TWEETS

medal descover
medal iphone